Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 10/20 | 0.46 |
| ▸ | DRD2 | P14416 | 9/20 | 0.46 |
| ▸ | HTR2A | P28223 | 8/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.46 |
| ▸ | HTR6 | P50406 | 7/20 | 0.46 |
| ▸ | HRH1 | P35367 | 7/20 | 0.46 |
| ▸ | HTR2C | P28335 | 6/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.46 |
| ▸ | HTR2B | P41595 | 5/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30357960 | 0.99 | DRD3 (0.46) | DRD3DRD2HTR2AOPRK1SLC6A3 | |
| SCHEMBL9666472 | 0.85 | HTR2A (0.47) | DRD3DRD2HTR2AOPRK1SLC6A3 | |
| SCHEMBL9383602 | 0.77 | DRD2 (0.41) | DRD3DRD2HTR2AOPRK1OPRM1 | |
| SCHEMBL4229226 | 0.73 | SIGMAR1 (0.56) | DRD3DRD2HTR2AOPRK1SLC6A3 | |
| SCHEMBL11268941 | 0.73 | DRD2 (0.49) | DRD3DRD2HTR2AOPRK1SLC6A3 | |
| SCHEMBL10692175 | 0.72 | DRD3 (0.45) | DRD3DRD2HTR2AOPRK1SLC6A3 | |
| Oxalic Acid SCHEMBL10562011 | 0.71 | DRD3 (0.45) | DRD3DRD2HTR2AOPRK1SLC6A3 | |
| SCHEMBL4379525 | 0.70 | DRD3 (0.58) | DRD3DRD2HTR2AOPRK1SLC6A3 | |
| SCHEMBL7295696 | 0.70 | SCN5A (0.58) | DRD3DRD2HTR2AOPRK1SLC6A3 | |
| SCHEMBL15469742 | 0.70 | DRD3 (0.51) | DRD3DRD2HTR2AOPRK1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | RESILIO COMPANY LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| EP-2946792-A1 | THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE& xA; | Resilio Company Limited (JP) | 2015-11-25 | — | — | EP | disclosed |
| WO-2015163318-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | レジリオ株式会社 | 2015-10-29 | — | — | WO | disclosed |
| US-20150126464-A1 | THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS | RESILIO COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| EP-2181704-B1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INT AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| EP-2559693-B1 | Polycyclic compound | EISAI R&D MAN CO LTD (JP) | 2014-11-26 | — | — | EP | disclosed |
| WO-2014112145-A1 | THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE | レジリオ株式会社 (JP) | 2014-07-24 | — | — | WO | disclosed |
| US-20050154454-A1 | Intravascular devices and fibrosis-inducing agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-20050149173-A1 | Intravascular devices and fibrosis-inducing agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050148512-A1 | fibrosis is induced by local or systemic release of specific pharmacological agents that become localized to the adjacent tissue; repair of tissues | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050147562-A1 | for treating or preventing gastroesophageal reflux disease (GERD) | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050147599-A1 | Fibrosing agent induces a fibrotic response at a specific site for treatment of urinary incontinence | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050147643-A1 | Treating varicose or veins by injecting a composition silk made of polyalkylene oxide-polyester block copolymer into the lumen of a vein; anchoring implantable medical devices into or onto biological tissue | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050149175-A1 | Intravascular devices and fibrosis-inducing agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050142163-A1 | Treatment for an orthopedic condition using agents such as silk or bleomycin | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-30 | — | — | US | disclosed |
| US-20040225077-A1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-11 | — | — | US | disclosed |
| WO-2004060346-A2 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | GAP43, NGF, BDNF | DRD3 2661/4885DRD2 2182/4885HTR2A 3418/4885 |
| US-20050148512-A1 | fibrosis is induced by local or systemic release of specific pharmacological agents that become localized to the adjacent tissue; repair of tissues | MMP1, CXCL12, MMP8 | DRD3 3815/4885DRD2 3656/4885HTR2A 2813/4885 |
| US-20150126464-A1 | THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS | BDNF, BACE1, GAP43 | DRD3 188/4885DRD2 383/4885HTR2A 1195/4885 |
| US-20050147643-A1 | Treating varicose or veins by injecting a composition silk made of polyalkylene oxide-polyester block copolymer into the lumen of a vein; anchoring implantable medical devices into or onto biological tissue | P4HB, ACVR2B, ACVR1 | DRD3 4675/4885DRD2 4819/4885HTR2A 4349/4885 |
| US-20050147599-A1 | Fibrosing agent induces a fibrotic response at a specific site for treatment of urinary incontinence | MMP1, FN1, COL2A1 | DRD3 4782/4885DRD2 4778/4885HTR2A 4093/4885 |
| US-20050147562-A1 | for treating or preventing gastroesophageal reflux disease (GERD) | HRH2, MMP1, FGF1 | DRD3 3908/4885DRD2 4205/4885HTR2A 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.